Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 1 Aug 2012

Je Eun M, An Chang H, Yoo Nam J, Lee Sug H

Abstract excerpt

Recent studies have revealed several recurrent mutations in oncogenes that could not only be underlying mechanisms of tumorigenesis, but also be potential targets for cancer therapies. Compared to carcinomas, genetic alterations of sarcomas are relatively unknown. To see whether recurrent oncogen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Enhancer of Zeste Homolog 2 Protein
Share to Forkhead Box Protein L2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forkhead Transcription Factors

Share to Janus Kinase 2

Share to Oncogenes

Share to Polycomb Repressive Complex 2

Share to Sarcoma

Source

Identifiers

PMID: 22779686
DOI: 10.1111/j.1600-0463.2012.02878.x

Genes

JAK2
AKT1
BRAF
FOXL2
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22779686-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.PMID 22779686Read ↗

Advances in sarcoma gene mutations and therapeutic targets.Semantic proximity Read ↗

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.Semantic proximity Read ↗

Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy TargetsSemantic proximity Read ↗

A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcomaSemantic proximity Read ↗

Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic ImplicationsSemantic proximity Read ↗

Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma BiologySemantic proximity Read ↗

[Molecular biology of soft-tissue sarcomas].Semantic proximity Read ↗

Dysregulation of miRNAs in Soft Tissue SarcomasSemantic proximity Read ↗

Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.Semantic proximity Read ↗

Anaplastic lymphoma kinase status in rhabdomyosarcomas.Semantic proximity Read ↗

Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.Semantic proximity Read ↗

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.